The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions.

A pharmaceutical composition is described. The chemically stable pharmaceutical composition comprises (i) a drug component consisting of mometasone, mometasone furoate, or a combination thereof, (ii) a propellant component comprising 1,1-difluoroethane (R-152a), and (iii) ethanol in an amount of from 0.5 to 10% by weight based on the total weight of the chemically stable pharmaceutical composition. The drug component comprises from 0.01 to 1.0 weight % of the total weight of the chemically stable pharmaceutical composition. At least 95 weight % of the propellant component is 1,1-difluoroethane (R-152a). The drug component is the sole drug component in the pharmaceutical composition. The chemically stable pharmaceutical composition is surfactant-free.

A pharmaceutical composition is described. The chemically stable pharmaceutical composition comprises (i) a drug component consisting of mometasone, mometasone furoate, or a combination thereof, (ii) a propellant component comprising 1,1-difluoroethane (R-152a), and (iii) ethanol in an amount of from 0.5 to 10% by weight based on the total weight of the chemically stable pharmaceutical composition. The drug component comprises from 0.01 to 1.0 weight % of the total weight of the chemically stable pharmaceutical composition. At least 95 weight % of the propellant component is 1,1-difluoroethane (R-152a). The drug component is the sole drug component in the pharmaceutical composition. The chemically stable pharmaceutical composition is surfactant-free.

The disclosure features immune cell delivery lipid nanoparticle (LNP) compositions that allow for enhanced delivery of agents, e.g., nucleic acids, such as therapeutic and/or prophylactic RNAs, to immune cells, in particular T cells, as well as B cells, dendritic cells and monocytes. The LNPs comprise an effective amount of an immune cell delivery potentiating lipid such that delivery of an agent by an immune cell delivery LNP is enhanced as compared to an LNP lacking the immune cell delivery potentiating agent. Methods of using the immune cell delivery LNPs for delivery of agents, e.g., nucleic acid delivery, for protein expression, for modulating immune cell activity and modulating immune responses are also disclosed.

Provided is a method of treating cancer cells localized in the lung by administering to such patients a therapeutically effective amount of a liposomal annamycin formulation (L-Ann).

Provided is a method of treating cancer cells localized in the lung by administering to such patients a therapeutically effective amount of a liposomal annamycin formulation (L-Ann).

The present disclosure provides a hydrogel having excellent drug delivery ability and having antibacterial properties as well as pH-dependent, biocompatible and biodegradable properties, and a method for preparing the same. The hydrogel including radiated chitosan, a natural gelling polymer, a hydrophilic synthetic polymer and (3-mercaptopropyl)trimethoxysilane (MPTMS), and the method for preparing the same are provided.

The present disclosure provides a hydrogel having excellent drug delivery ability and having antibacterial properties as well as pH-dependent, biocompatible and biodegradable properties, and a method for preparing the same. The hydrogel including radiated chitosan, a natural gelling polymer, a hydrophilic synthetic polymer and (3-mercaptopropyl)trimethoxysilane (MPTMS), and the method for preparing the same are provided.

The present disclosure provides a compound that exerts an anticancer action based on CHK1 inhibition. The present disclosure was completed by finding that a compound represented by formula (1) or a pharmaceutically acceptable salt thereof exhibits an excellent antitumor action by having a potent inhibitory action against CHK1:

##STR00001##

wherein R.sup.1, R.sup.2, L, V, W, and Q are as defined herein, X, Y, and Z each independently represent CR.sup.8 or a nitrogen atom, wherein X, Y, and Z are not simultaneously CR.sup.8, and R.sup.8 is as defined herein.